Neumora Therapeutics, Inc. Common Stock
Stock Forecast, Prediction & Price Target
Neumora Therapeutics, Inc. Common Stock Financial Estimates
Neumora Therapeutics, Inc. Common Stock Revenue Estimates
Neumora Therapeutics, Inc. Common Stock EBITDA Estimates
Neumora Therapeutics, Inc. Common Stock Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $36.21M Low: $36.21M High: $36.21M avg. 0% | ||
Net Income
% change YoY
| $-237.31M N/A | $-130.90M 44.83% | $-235.92M -80.22% | Avg: $-270.84M Low: $-265.91M High: $-214.55M avg. -14.80% | Avg: $-323.03M Low: $-322.13M High: $-226.40M avg. -19.26% | ||
EBITDA
% change YoY
| $-236.78M N/A | $-135.27M 42.86% | $-187.52M -38.62% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | ||
EPS
% change YoY
| -$1.56 N/A | -$0.86 44.87% | -$1.49 -73.25% | Avg: -$1.57 Low: -$1.75 High: -$1.41 avg. -5.12% | Avg: -$1.71 Low: -$2.12 High: -$1.49 avg. -8.93% | ||
Operating Expenses
% change YoY
| $237.32M N/A | $135.87M -42.74% | $187.52M 38.01% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | ||
FAQ
What is Neumora Therapeutics, Inc. Common Stock stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -17.03% in 2025-2026.
We have gathered data from 5 analysts. Their low estimate is -265.91M, average is -270.84M and high is -214.55M.
What is Neumora Therapeutics, Inc. Common Stock stock revenue growth forecast?
We have gathered data from 6 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Neumora Therapeutics, Inc. Common Stock stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -7.03% in 2025-2026.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.75, average is -$1.57 and high is $-1.41.
What is the best performing analyst?
In the last twelve months analysts have been covering Neumora Therapeutics, Inc. Common Stock stock. The most successful analyst is Graig Suvannavejh.